Bayer: Legacy Issues Are Being Set Aside and Focus is Redirected Towards Future Opportunities!

The Bayer stock has been a cause for concern for investors for many years. However, last year laid the groundwork for a turnaround, which is being built on an increasingly stable foundation. This trend was also evident on August 4, when the company was able to surpass its revenue and adjusted EBITDA forecasts for the second quarter. It is also positive that they are increasingly shedding legacy issues. For example, the US glyphosate business is being consolidated into Ruveon LLC. Additionally, debt reduction is also in focus. Through the recently...